The effect of QuYuHuaTanTongLuo Decoction on the non-alcoholic steatohepatitis

Complementary Therapies in Medicine

Volumn 16, Issue 4, 2008, Pages 192-198

  Zhang, Shi Jun ^a   Chen, Ze Xiong ^a   Jiang, Kai Ping ^b   Cheng, Yong Hua ^a   Gu, Yan Li ^c  

^a SUN YAT SEN UNIVERSITY   (China)

^b Guangzhou Universtiy of Chinese Medicine   (China)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Non alcoholic steatohepatitis; QuYuHuaTanTongLuo Decoction

Indexed keywords

BUPLEURUM ROOT; CHINESE DRUG; CHOLESTEROL; CODONOPSIS PILOSULA EXTRACT; GLYCYRRHIZA PRAEPARATA EXTRACT; HEDYOTIS DIFFUSA EXTRACT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MORINDA OFFICINALIS EXTRACT; MYELOPEROXIDASE; PINELLIA EXTRACT; PLANT EXTRACT; POLYGONUM CUSPIDATUM EXTRACT; QUYUHUATANTONGLUO; SCUTELLARIAE RADIX; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; URSODEOXYCHOLIC ACID; ZIZIPHI JUJUBA EXTRACT;

ABSENCE OF SIDE EFFECTS; ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; B SCAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; EPIGASTRIC PAIN; FATIGUE; FEMALE; GLYCYRRHIZA PRAEPARATA; HUMAN; LIPID PEROXIDATION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MORINDA OFFICINALIS; NAUSEA; NONALCOHOLIC FATTY LIVER; PLANT; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SYMPTOM; TREATMENT DURATION; ZIZIPHI JUJUBA;

ADOLESCENT; ADULT; DRUGS, CHINESE HERBAL; FATTY LIVER; FEMALE; HUMANS; INTERLEUKIN-8; LIPIDS; MALE; MIDDLE AGED; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTORS;

EID: 47049131249     PISSN: 09652299     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctim.2007.08.004     Document Type: Article

References (38)

1. Chen C.H., Huang M.H., Yang J.C., Nien C.K., Yang C.C., Yeh Y.H., et al. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of Taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J Clin Gastroenterol 40 8 (2006) 745-752
2. Bellentani S., Saccoccio G., Masutti F., Croce L.S., Brandi G., Sasso F., et al. Prevalence of and risk factors for hepatic steatosis in northern Italy. Ann Intern Med 132 (2000) 112-117
3. Shen L., Fan J.G., Shao Y., Zeng M.D., Wang J.R., Luo G.H., et al. Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. World J Gastroenterol 9 5 (2003) 1106-1110
4. Daniel S., Ben-Menachem T., Vasudevan G., Ma C.K., and Blumenkehl M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 94 (1999) 3010-3014
5. Wong V.W., Chan H.L., Hui A.Y., Chan K.F., Liew C.T., Chan F.K., et al. Clinical and histological features of non-alcoholic fatty liver disease in Hong Kong Chinese. Aliment Pharmacol Ther 20 1 (2004) 45-49
6. Hui A.Y., Wong V.W., Chan H.L., Liew C.T., Chan J.L., Chan F.K., et al. Histological progression of non-alcoholic fatty liver disease in Chinese patients. Aliment Pharmacol Ther 21 4 (2005) 407-413
7. Fan J.G., Zhu J., Li X.J., Chen L., Lu Y.S., Li L., et al. Fatty liver and the metabolic syndrome among Shanghai adults. J Gastroenterol Hepatol 20 12 (2005) 1825-1832
8. Fan J.G., Zhu J., Li X.J., Chen L., Li L., Dai F., et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol 43 3 (2005) 508-514
9. Adams L.A., Lymp J.F., St Sauver J., Sanderson S.O., Lindor K.D., Feldstein A., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129 1 (2005) 113-121
10. Comar K.M., and Sterling R.K. Review article: drug therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther 23 2 (2006) 207-215
11. Adams L.A., and Angulo P. Treatment of non-alcoholic fatty liver disease. Postgrad Med J 82 967 (2006) 315-322
12. Farrell G.C., and Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43 2 Suppl. 1 (2006) S99-S112
13. Maheshwari A., and Thuluvath P.J. Cryptogenic cirrhosis and NAFLD: are they related?. Am J Gastroenterol 101 3 (2006) 664-668
14. Te Sligte K., Bourass I., Sels J.P., Driessen A., Stockbrugger R.W., and Koek G.H. Non-alcoholic steatohepatitis: review of a growing medical problem. Eur J Intern Med 15 1 (2004) 10-21
15. Malaguarnera L., Madeddu R., Palio E., Arena N., and Malaguarnera M. Heme oxygenase-1 levels and oxidative stress-related parameters in non-alcoholic fatty liver disease patients. J Hepatol 42 4 (2005) 585-591
16. American Gastroenterological Association. American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease. Gastroenterology 123 5 (2002) 1702-1704
17. Fatty Liver and Alcoholic Liver Disease Study Group of Chinese Liver Disease Association. Diagnostic criteria of nonalcoholic fatty liver disease. Zhonghua Ganzangbing Zazhi 2003;11:71.
18. Eckel R.H., Grundy S.M., and Zimmet P.Z. The metabolic syndrome. Lancet 365 9468 (2005) 1415-1428
19. Lonardo A., and Trande P. Are there any sex differences in fatty liver? A study of glucose metabolism and body fat distribution. J Gastroenterol Hepatol 15 (2000) 775-782
20. Dixon J.B., Bhathal P.S., and O'Brien P.E. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement. Obes Surg 16 10 (2006) 1278-1286
21. Paolicchi A., Minotti G., Tonarelli P., Tongiani R., De Cesare D., Mezzetti A., et al. Gamma-glutamyl transpeptidase-dependent iron reduction and LDL oxidation-a potential mechanism in atherosclerosis. J Invest Med 47 3 (1999) 151-160
22. Ikura Y., Ohsawa M., Suekane T., Fukushima H., Itabe H., Jomura H., et al. Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: impact on disease progression. Hepatology 43 3 (2006) 506-514
23. Mehta K., Van Thiel D.H., Shah N., and Mobarhan S. Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants. Nutr Rev 60 9 (2002) 289-293
24. Malaguarnera L., Rosa M.D., Zambito A.M., dell'Ombra N., Marco R.D., and Malaguarnera M. Potential role of chitotriosidase gene in nonalcoholic fatty liver disease evolution. Am J Gastroenterol 101 9 (2006) 2060-2069
25. Bahcecioglu I.H., Yalniz M., Ataseven H., Ilhan N., Ozercan I.H., Seckin D., et al. Levels of serum hyaluronic acid, TNF-alpha and IL-8 in patients with nonalcoholic steatohepatitis. Hepatogastroenterology 52 65 (2005) 1549-1553
26. Poniachik J., Csendes A., Diaz J.C., Rojas J., Burdiles P., Maluenda F., et al. Increased production of IL-1alpha and TNF-alpha in lipopolysaccharide-stimulated blood from obese patients with non-alcoholic fatty liver disease. Cytokine 33 5 (2006) 252-257
27. Agrawal S., and Bonkovsky H.L. Management of nonalcoholic steatohepatitis: an analytic review. J Clin Gastroenterol 35 3 (2002) 253-261
28. Harrison S.A., and Di Bisceglie A.M. Advances in the understanding and treatment of nonalcoholic fatty liver disease. Drugs 63 22 (2003) 2379-2394
29. Athyros V.G., Mikhailidis D.P., Didangelos T.P., Giouleme O.I., Liberopoulos E.N., Karagiannis A., et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 22 5 (2006) 873-883
30. Kwon H.J., Kim Y.Y., and Choung S.Y. Amelioration effects of traditional Chinese medicine on alcohol-induced fatty liver. World J Gastroenterol 11 35 (2005) 5512-5516
31. Zhang S.J., Chen Z.X., Lao S.X., and Huang B.J. Observation on effect of treatment of alcoholic fatty liver by traditional medicine therapy of clearing liver, removing dampness and dredging collaterals. CJIM 8 2 (2002) 81-84
32. Chen Z.X., Zhang S.J., and Yun L.R. Clinical study of treatment nonalcoholic fatty liver with qianggan capsule. Zhongguo Zhong Yao Za Zhi 31 20 (2006) 1739-1741
33. In: Wang B.X. (Ed). Liver and gallbladder diseases in traditional Chinese medicine (1993), Chin Publishing House of Med Scien and Tech, Beijing 60-113
34. Kiyici M., Gulten M., Gurel S., Nak S.G., Dolar E., Savci G., et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol 17 12 (2003) 713-718
35. Ersoz G., Gunsar F., Karasu Z., Akay S., Batur Y., and Akarca U.S. Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment. Turk J Gastroenterol 16 3 (2005) 124-128
36. Suzuki A., Lymp J., Sauver J.S., Angulo P., and Lindor K. Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis. Liver Int 26 10 (2006) 1209-1216
37. Sabir N., Sermez Y., Kazil S., and Zencir M. Correlation of abdominal fat accumulation and liver steatosis: importance of ultrasonographic and anthropometric measurements. Eur J Ultrasound 14 2/3 (2001) 121-128
38. Moriyasu F., Iijima H., Tsuchiya K., Miyata Y., Furusaka A., and Miyahara T. Diagnosis of NASH using delayed parenchymal imaging of contrast ultrasound. Hepatol Res 33 2 (2005) 97-99